Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin-induced thrombocytopenia.

Beng H Chong1, James J H Chong

  • 1Department of Medicine, St George Clinical School and Centre of Vascular Research, University of New South Wales, Sydney, New South Wales, USA. beng.chong@unsw.edu.au

Expert Review of Cardiovascular Therapy
|July 1, 2004
PubMed
Summary

Heparin can cause a dangerous immune reaction called Type II heparin-induced thrombocytopenia (HIT), leading to blood clots and severe complications. Understanding HIT

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Image Integration to Identify Histologic and Electroanatomic Ventricular Scar: A Clinicopathological Study Comparing 2 Image Integration Systems.

JACC. Clinical electrophysiology·2026
Same author

Device encapsulated MSCs for adaptive secretome therapy to effectively target ischaemic heart injury.

Stem cell research & therapy·2025
Same author

Human Hearts Intrinsically Increase Cardiomyocyte Mitosis After Myocardial Infarction.

Circulation research·2025
Same author

Immune regulation following allogeneic iPSC-derived cardiomyocyte transplantation in non-human primates.

Cardiovascular research·2025
Same author

Platelet derived growth factor-AB modulates post-infarct myocardium leading to extended improvement in cardiac function.

NPJ Regenerative medicine·2025
Same author

Comparison of Extrastimulus Pacing Strategies for the Detection of Arrhythmogenic Substrate for Ventricular Tachycardia: Insights From a Porcine Ischemia-Reperfusion Injury Model.

Circulation. Arrhythmia and electrophysiology·2025

Area of Science:

  • Immunology
  • Hematology
  • Pharmacology

Background:

  • Heparin is a critical anticoagulant for thrombotic and cardiovascular conditions.
  • Type II heparin-induced thrombocytopenia (HIT) affects 0.5–3.0% of patients on heparin.
  • HIT involves thrombocytopenia, thrombosis, and potentially fatal outcomes.

Purpose of the Study:

  • To review the incidence, pathophysiology, clinical presentation, diagnosis, and management of HIT.
  • To highlight the association between HIT and cardiac surgery.
  • To elucidate the immunological basis of HIT.

Main Methods:

  • Review of existing literature on heparin-induced thrombocytopenia.
  • Discussion of the immunological mechanisms involving heparin and platelet factor 4.
  • Analysis of clinical data regarding HIT frequency and risk factors.

Main Results:

  • HIT is an immune reaction mediated by IgG antibodies against the heparin-platelet factor 4 complex.
  • Recent surgery, especially cardiac surgery, is a significant risk factor for developing HIT antibodies.
  • While many patients develop antibodies, only a fraction progress to clinical HIT.

Conclusions:

  • HIT is a serious adverse drug reaction with significant morbidity and mortality.
  • Early diagnosis and appropriate management are crucial for patient outcomes.
  • Further research into HIT pathophysiology and prevention is warranted.

Related Experiment Videos